background: Endometriosis is characterized by ectopic implantation of endometrial cells, which show increased proliferation and migration. Somatostatin (SST) and its analogues inhibit normal and cancer cell growth and motility through the SST receptors, sst1 -5. Cortistatin (CST), which displays high structural and functional homology with SST, binds all ssts, as well as MrgX2. Our objective was to investigate the gene expression of the SST/CST system and to determine the effect of SST and its analogues on platelet-derived growth factor (PDGF)-induced proliferation and motility in telomerase-immortalized human endometrial stromal cell (T HESC) line and in primary endometrial stromal cell (ESCs) isolated from human endometriotic tissues.
Introduction gonadotrophin-releasing hormone (GnRH) analogues, as well as growth hormone-releasing hormone (GHRH) antagonists, were shown to exert direct anti-proliferative effects in endometriotic cells, which express GnRH and GHRH receptors (Meresman et al., 2003; Morimoto et al., 2005; Fu et al., 2009; Annunziata et al., 2010) .
Somatostatin (SST) was originally described as a hypothalamic peptide inhibiting pituitary growth hormone secretion (Brazeau et al., 1973) , but it is also expressed in many peripheral tissues, where it inhibits hormone secretion and cell proliferation (Weckbecker et al., 2003) . SST binds to a family of G-protein-coupled receptors (GPCRs) termed SST receptors (ssts), which are widely distributed in the human body. The ssts family includes five subtypes, sst1 -sst5 (Weckbecker et al., 2003) and two recently discovered truncated variants of the sst5, sst5TMD5 and sst5TMD4 (Duran-Prado et al., 2009) . Sst2 has been detected in normal human endometria (Green et al., 2002) and, recently, high sst1, sst2 and sst5 expression has been shown in endometriotic lesions (Fasciani et al., 2010) . Moreover, immunoreactive ssts have been found in endometrial cancer tissues (Schulz et al., 2003) and cells (Mishima et al., 1999) .
Ssts are the target of long-acting synthetic SST analogues, that are successfully used for the treatment of neuroendocrine tumours, and exert anti-proliferative effects on several cell types (Weckbecker et al., 2003) . They differ in their binding affinity to the five ssts, e.g. the octapeptide SMS201-995 (Octreotide) is a preferential sst2 ligand, while the cyclohexapeptide SOM230 (Pasireotide) binds with high affinity to sst5, sst2, sst1 and sst3 (Weckbecker et al., 2003) .
Finally, ssts also transduce the signal of cortistatin (CST), a peptide that is distributed in normal and tumoral tissues. CST shows great structural and functional homology to SST (Spier and de Lecea, 2000; Gahete et al., 2008) , but also important differences, such as in the expression pattern and regulation of immune system (Broglio et al., 2007; Gahete et al., 2008) . Besides all ssts, CST is able to bind another GPCR called MAS-related gene X2 (MrgX2), which is not recognized by SST (Robas et al., 2003; Gahete et al., 2008) . Based on the broad expression of ssts and on the inhibitory effects of SST in different cell types, we hypothesized that SST and its analogues may reduce endometrial cell proliferation and migration.
The dimeric protein platelet-derived growth factor (PDGF), whose monomers are encoded by four different genes, PDGF-(A -D), is considered one of the major regulators of endometrial cell biology (Matsumoto et al., 2005) . Indeed, distinct PDGF isoforms, especially PDGF-BB, have been shown to stimulate endometrial cell proliferation, invasiveness and migration (Surrey and Halme, 1991; Chegini et al., 1992; Matsumoto et al., 2005; Gentilini et al., 2007) . Since PDGF was also found in endometrial tissues and in the peritoneal fluid of women with endometriosis (Boehm et al., 1990; Chegini et al., 1992; Overton et al., 1996; Kalu et al., 2007) , we aimed at evaluating SST effects on basal and PDGF-induced cell proliferation and migration. As cell models, we used the telomerase-immortalized human endometrial stromal cell (T HESC) line, which represents uterine endometrial cells from healthy women, and primary endometrial stromal cells (ESCs) isolated from human endometriotic tissues. Therefore, in the present study, we first investigated the expression of the SST/CST system in endometriotic tissues, ESCs and T HESCs. Next, we determined the biological effects of SST, of ssts selective/preferential agonists and CST on PDGF-induced endometrial cell growth and motility. In addition, we examined the signalling pathways involved in these effects.
Materials and Methods

Peptides and reagents
Human SST-14 and CST-17 were purchased from Phoenix Pharmaceuticals (Burlingame, CA, USA), recombinant PDGF-BB was from PeproTech (Rocky Hill, NJ, USA). The sst1 agonist BIM-23926 was kindly provided by Dr Michael D. Culler (Ipsen, Boston, MA, USA). SOM230 was kindly provided by Dr Herbert Schmid (Novartis, Switzerland) and Octreotide was a generous gift from Novartis (Spain). phenol red-free Dulbecco's modified Eagle's medium (DMEM)/F-12 medium, fetal bovine serum (FBS) and charcoal-stripped FBS were purchased from Gibco (San Giuliano Milanese, Milan, Italy), type-I collagenase, bovine gelatine 2% solution, penicillin, streptomycin, puromycin and amphotericin B from Sigma (Milan, Italy) and ITS + Premix from BD Biosciences (Buccinasco, Milan, Italy).
Patients and sample collection
Ectopic endometrial tissues were obtained by laparoscopy from 23 women suffering from endometriosis (age range: 35.6 + 5.9 years). Final diagnosis was confirmed by histopathological examination. According to the revised American Society for Reproductive Medicine classification, stages of endometriosis were III (56%) or IV (44%). The study and investigation protocols were approved by the Ethical Committee of the University of Turin School of Medicine, and all patients gave informed consent to the study. All of the patients had regular menstrual cycles and none had received hormonal treatment in the 3 months preceding surgery. Endometriotic tissues were immediately used for cell culture or snap frozen in liquid nitrogen and stored at 2808C for expression analysis.
Isolation of primary human ESCs
ESCs were isolated from endometriotic tissues as previously described (Annunziata et al., 2010) . ESCs were cultured in phenol red-free DMEM/F-12 medium (Gibco) reconstituted with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin and 250 ng/ml amphotericin B. The purity of ESC preparation was greater than 96%, according to positive cellular staining for vimentin and negative staining for cytokeratin and CD45. RNA was extracted from ESC at the first passages.
Immortalized T HESC line
T HESC, a human cell line of control, eutopic ESCs immortalized with telomerase, was purchased by American Type Culture Collection (ATCC). T HESCs are karyotypically and morphologically similar to the primary parent cells, and were cultured in phenol red-free DMEM/F-12 supplemented with 1% ITS + Premix, 500 ng/ml puromycin and 10% heat-inactivated, charcoal-stripped FBS. The cells were cultured in a humidified atmosphere at 378C in 5% CO 2 .
RNA extraction, reverse transcription and quantitative PCR Total RNA isolation and reverse transcription were performed as previously described ) from endometriotic tissues (n ¼ 7), primary ESCs (three different cell preparations) and T HESCs. RNA samples were treated with DNA-free DNase according to manufacturer instructions (LifeTech, Monza, Italy). Primer pairs (Table I) were designed with Primer-3 software (http://frodo.wi.mit.edu/, 24 April, 2012, date last accessed; Steve Rozen, Whitehead Institute for Biomedical Research) and synthesized by Bonsai technologies (Madrid, Spain), and all had an optimal annealing temperature at 618C. The housekeeping genes b-actin or 18S were used as an internal standard for gene expression screening and for experiments performed in the presence of PDGF, respectively. Real-time PCR reactions were performed with 50 ng of cDNA, 150 nM of each primers and the IQ-SYBR-green mastermix (BioRad, Madrid, Spain). All PCR reactions were carried out in an iCycler IQ TM termal cycler (BioRad).
Cell proliferation
T HESC and ESC proliferation was evaluated by measuring the reduction of Alamar-blue reagent (Biosource International) according to the indications of the supplier. This compound is reduced by viable cells, and the amount of the Alamar blue reduced is directly proportional to the cell number. Briefly, 3 × 10 3 cells/well were seeded in a 96-well plate, serum starved 24 h and incubated for additional 48 h in serum-free medium with SST and its analogues, in either the presence or absence of PDGF. Finally, the cells were incubated for 2 h in 10% Alamar blue/ serum free-medium, and Alamar reduction was measured in a BioTek Synergy HT fluorescence plate reader (BioTek Instruments, Inc., Vermont, USA), exciting at 560 nm and reading at 590 nm.
Wound healing assay
T HESCs were plated in 12-well plates (4 × 10 4 cells/well), cultured until confluence and then serum starved for 24 h. A scratch was then created in the monolayer with a 10 ml pipet tip and the medium was replaced by a fresh serum-free medium containing SST and its analogues in either the presence or absence of PDGF. Five representative images per well were captured along the wound at time 0 and after 16 h, and analyzed with ImageJ (http://rsbweb.nih.gov/ij/, 24 April, 2012, date last accessed). Percentage of wound closure was calculated by measuring on each image the area of a 400 pixels width rectangle without cells, at 16 h and just after doing the scratch.
Immunofluorescence
T HESCs and ESCs were cultured onto glass coverslips, fixed in 3% paraformaldehyde, permeabilized with 0.2% Triton X-100 and incubated 1 h in 1% BSA (blocking buffer). Cells were stained overnight at 48C with goat antibodies against sst1-5 from Santa Cruz Biotechnologies (DBA Italia, Segrate, Milan, Italy), or rabbit antibodies against CST, SST and MrgX2 from LifeSpan BioSciences (Space Import Export, Milan, Italy). Cells were then washed and incubated 1 h at room temperature with phycoerythrin-conjugated anti-goat or AlexaFluor488-conjugated antirabbit antibodies (Invitrogen, Milan, Italy). Cell nuclei were stained with Hoechst 33258 (Sigma). After additional washes, slides were mounted and images acquired with a Leica DM200 fluorescent microscope. To analyse cytoskeleton reorganization, cells were cultured onto gelatincoated glass coverslips, serum starved for 24 h and then treated for 15 min with the indicated peptides in serum-free medium. Cells were fixed in cold methanol, incubated for 1 h in blocking buffer and stained with the monoclonal antibody for b-actin (Sigma). AlexaFluor488-conjugated anti-mouse antibodies (Molecular Probes, Barcelona, Spain) were used as secondary antibody. Pictures were obtained using a Nikon Eclipse TE2000 E microscope (Nikon, Tokyo, Japan) using a 20× objective. To quantify the effects of the peptides, cells with a static and a migratory phenotype were counted. At least 100 cells were counted for each sample, and cells with migratory phenotype were considered positive. Results are expressed as percentage of positive cells normalized over the control.
Western blotting
Cells were cultured to subconfluence in 6-well plates, serum starved and treated 0 -30 min with SST or SOM230, either in the presence or absence of PDGF. Subsequently, the proteins were extracted and processed as previously described (Annunziata et al., 2010) . Membranes were incubated with the primary antibodies for ERK1/2, P-ERK1/2, P-Akt and Akt (Cell Signalling, Boston, MA) and the appropriate secondary antibodies conjugated to peroxidase. Bands were revealed using the Amersham ECL-Plus detection system (GE Healthcare, UK). A densitometric analysis of the bands was performed with ImageJ software.
Statistics
Data are expressed as the mean + SEM. Calculations were performed using GraphPad Prism version 5.0 software (GraphPad Software, Inc., San Diego, CA 
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Results
SST, ssts and PDGF expression in endometriotic tissues and cells, and in the T HESC cell line
To evaluate the role of SST/CST in endometriosis, we first assessed the mRNA expression of SST, CST and their receptors in endometriotic tissues, primary ESCs and in T HESC line. Both endometriotic tissues and ESCs expressed all ssts ( Fig. 1A and C) . T HESCs mainly expressed sst1 and low levels of sst2 and 3, while sst4 and 5 transcripts were not detectable (Fig. 1E) . SST mRNA was found in endometriotic tissues and cells ( Fig. 1A and C) , whereas it was weakly expressed in T HESCs (Fig. 1E) . To confirm the PDGF presence in endometriotic tissues, and possible PDGF responsiveness in endometrial cells, we also examined PDGF mRNA in endometriotic tissues and cells, and PDGF receptors mRNA in ESCs and T HESCs. PDGF-A and -B chain mRNAs were detected in endometriotic tissues (Fig. 1B) , ESCs ( Fig. 1D ) and T HESCs (Fig. 1F) . Moreover, both ESCs and T HESCs expressed the PDGF receptors PDGF-Ra and PDGF-Rb (Fig. 1G ).
SST and ssts proteins localization in primary ESCs and T HESC cell line
We then investigated the protein expression and subcellular localization of sst1-5 and SST in primary ESCs and T HESC cell line. In primary ESCs sst1, sst2, sst3, sst4 and sst5 were present both at the plasma membrane and intracellularly. Notably, sst2 was the receptor more frequently localized at the intracellular level. SST was found expressed and distributed in the perinuclear area (Fig. 2) . Similar results were observed in T HESCs, with a weak expression of sst4 and ss5 (Fig. 2) .
SST and its analogues reduce PDGF-induced ESC and T HESC cell proliferation
We then investigated whether SST and its analogues would interfere with PDGF-induced cell proliferation. PDGF increased the number of viable T HESCs (Fig. 3A) , and this effect was counteracted by either SST (10 nM) or SOM230 (10 nM and 1000 nM; Fig. 3A ). Dose -response experiments with SST at concentrations ranging from 0.1 to 1000 nM confirmed that the most effective SST concentration was 10 nM (data not shown). Conversely, octreotide and the sst1 agonist BIM-23926 had no effect (Fig. 3A) . In primary ESCs, SST and SOM230 suppressed the PDGF-induced increase in cell proliferation (Fig. 3B) . Neither SST nor its analogues affected ESC or T HESC proliferation in serum-free medium alone, without PDGF (data not shown).
SST and its analogues counteract PDGF-induced cell motility in ESCs and T HESCs PDGF strongly increased T HESC motility (Fig. 4A ). SST and SOM230 reduced PDGF-induced cell motility at both 10 and 1000 nM, whereas octreotide and BIM-23926 were effective only at the highest concentration tested ( Fig. 4A and B) . The highest dose of SST, octreotide and BIM-23926 did not affect T HESC motility in the absence of PDGF, whereas SOM230 reduced it. Interestingly, SST, octreotide and BIM-23926, but not SOM230, slightly increased T HESC motility, when tested at the lowest dose (10 nM; Fig. 4A and B).
The inhibitory effect of SST analogues on PDGF-induced endometrial cell motility was further confirmed by evaluating actin cytoskeleton The somatostatin system in endometriosis rearrangement, which is required for cell migration (Gentilini et al., 2010) . In both T HESCs and primary ESCs, short-term treatment with PDGF induced b-actin accumulation along cell edges and lamellipodia formation. Co-treatment with SST or its analogues reduced the number of cells with migratory phenotype (Fig. 4C and D) .
SST modulates vascular endothelial growth factor and metalloprotease-2 gene expression in ESCs and T HESCs
We evaluated whether short-(4 h) or long (24 h) term treatment with SST, in either the absence or presence of PDGF, would influence gene expression of metalloprotease-2 (MMP-2) and vascular endothelial growth factor (VEGF). In both T HESCs and ESCs, SST reduced basal MMP-2 expression at 24 h, whereas it had no effect at 4 h ( Fig. 5A and B) . On the other side, SST counteracted PDGF-induced increase in MMP-2 at 4 h in T HESCs (Fig. 5A) . Similarly, in ESCs, SST reduced MMP-2 expression at 24 h in the presence of PDGF, even though the increase induced by PDGF was not significant (Fig. 5B) . SST alone also reduced VEGF mRNA, at both 4 and 24 h in T HESCs, and at 4 h in ESCs. Conversely, PDGF had no effect on VEGF expression, at any of the time points tested (Fig. 5C and D) .
SST and its analogues reduce basal and PDGF-induced phosphorylation of ERK1/2
We investigated the effect of PDGF, SST and SOM230 on the activation of MAPK ERK1/2 and phosphatidylinositol 3-kinase (PI3-K)-dependent Akt in T HESCs. PDGF strongly stimulated ERK1/2 and Akt phosphorylation( Fig. 6A and C) . Activation of ERK1/2 occurred as early as 5 min after stimulation, peaked at 15 min and lasted at least 30 min. Both SST and SOM230 increased PDGF-induced ERK1/2 phosphorylation at 5 min, whereas at 15 and 30 min they reduced the PDGF stimulatory effect (Fig. 6A) . Similarly, SST increased P-ERK1/2 at 5 min in serum-free medium in the absence of PDGF and strongly reduced it at 30 min. SOM230 reduced basal ERK1/2 activation at all the tested time points (Fig. 6B ). SST and SOM 230 increased both basal and PDGF-induced Akt phosphorylation at 5 min, whereas they had no effect at the later time points tested ( Fig. 6C and D) .
CST is expressed in endometriotic tissues and cells, and reduces PDGF-induced endometrial cell proliferation and motility
Endometriotic tissues, primary ESCs and T HESCs expressed CST mRNA (Fig. 7A) . MrgX2 mRNA was detected in endometriotic tissues and ESCs, but not T HESCs (Fig. 7A) . Furthermore, the CST peptide was detected in both ESC and T HESC. MrgX2 protein was mostly intracellular and only occasionally detectable at the cell membrane of primary ESCs. T HESCs displayed very weak staining for MrgX2 and only at intracellular localization (Fig. 7B) . In T HESCs, CST inhibited PDGF-induced proliferation at 10 nM but not at 1000 nM, whereas it showed no effect at both concentrations in ESCs (Fig. 7C) . CST, at the highest concentration tested (1000 nM) also inhibited PDGF-induced cell migration in both T HESCs and ESCs (Fig. 7D) , whereas it showed no effect at lower concentrations (data not shown).
Discussion
The present study shows that human endometriotic tissues, primary endometrial stromal cells (ESCs) and the endometrial T HESC line express SST and its receptors. Furthermore, SST and its synthetic analogues counteracted PDGF-induced cell proliferation and motility in primary ESCs and in the T HESC line. SST also reduced VEGF and MMP-2 gene expression and ERK1/2 activation. Finally, the mRNA and protein of the natural SST analogue CST were found to be expressed in endometriotic tissues and cells, and like SST, exogenous CST inhibited PDGF-induced endometrial cell motility. The somatostatin system in endometriosis Sst2 expression has been previously shown in the normal human endometrium (Green et al., 2002) , and ssts have been detected in endometrial cancer tissues and cells (Mishima et al., 1999; Schulz et al., 2003) . Sst1, 2 and 5 proteins were recently found in endometriotic lesions in both stromal and epithelial compartment (Fasciani et al., 2010) . No data are instead available on sst3 and sst4 expression in endometriotic tissues, on ssts expression in cultured ESCs and T HESCs or on CST/MrgX2 in endometriotic cells and tissues.
Here, we show gene expression of SST and all its receptors in endometriotic tissues and cells, and further confirm this finding in primary ESCs and T HESCs by showing ssts protein expression. Interestingly, we detected sst4 and sst5 expression in T HESCs by immunofluorescence but not by real-time PCR. This might depend on multiple factors (Pascal et al., 2008) , such as post-transcriptional mechanisms impairing mRNA stability or slow protein turnover. However, our result awaits further confirmation when additional antibodies against ssts will be available. We could also detect the endogenous SST peptide in ESCs and T HESCs, suggesting the existence of an autocrine loop. Interestingly, SST has been previously shown to cause sst2 internalization (Reubi et al., 2000) , which could at least partly explain the cytoplasmic sst2 staining observed in the present study. Notably, CST mRNA and peptide were found here to be expressed in ESCs and T HESCs. Given the inflammatory nature of endometriosis and the immunomodulatory properties of CST (Spier and de Lecea, 2000; Gahete et al., 2008) , this finding suggests that CST may play a role in regulating local inflammation. Further studies should aim at elucidating this important aspect.
Since endometrial cell proliferation is a key step in the progression of endometriosis (Giudice and Kao, 2004; Aghajanova et al., 2010) , we investigated whether SST would inhibit either basal or PDGF-induced proliferation of ESCs and T HESCs. We chose PDGF because it is a known mitogen for ESCs (Surrey and Halme, 1991; Chegini et al., 1992; Matsumoto et al., 2005) and is involved in several inflammatory diseases, including endometriosis (Overton et al., 1996; Laschke et al., 2006; Kalu et al., 2007; Andrae et al., 2008) . PDGF-A and B transcripts were detected in endometriotic tissues, ESCs and T HESCs, in keeping with previous data in the normal endometrium (Boehm et al., 1990; Chegini et al., 1992) . As expected, we also found that ESCs and T HESCs expressed PDGF receptors, and PDGF-promoted ESC and T HESC proliferation. On these bases, we hypothesized that SST and its analogues, which exert anti-proliferative effects (Weckbecker et al., 2003) , would reduce PDGF-induced cell proliferation. We found that SST and SOM230, the two pan-ligands of ssts, counteracted PDGF-induced proliferation in ESCs and T HESCs. Conversely, selective or preferential stimulation of receptor subtypes 1 and 2 (by BIM-23926 and octreotide, respectively) had not anti-proliferative effect. This suggests that co-activation of multiple ssts may lead to synergistic effects, likely due to receptor cross-talk or heterodimerization , in keeping with previous observations (Barbieri et al., 2008) . Notably, SST caused a maximal inhibition of PDGF-induced ESCs and T HESCs proliferation at concentrations of 10 nM, and not at 1000 nM, which is consistent with previous reports (Cattaneo et al., 1996) . This may reflect different receptor dimerization and internalization dynamics elicited by high/low concentrations of the ligand (Grant et al., 2004; Duran-Prado et al., 2008) .
Besides proliferation, PDGF was previously shown to stimulate migration of normal (Matsumoto et al., 2005; Gentilini et al., 2007) and . Cells were incubated in serum-free medium alone (c, control), with SST (S, 1000 nM), PDGF (P, 10 ng/ml) or SST and PDGF (P + S), for 4 or 24 h. Gene expression was assessed by real-time PCR. Results, normalized to 18S rRNA, are expressed as percent of control and are the mean + SEM of four independent experiments (*P , 0.05; **P , 0.01; ns, not significant).
endometriotic ESCs (Gentilini et al., 2010) . Because ESCs of women suffering from endometriosis have enhanced migratory potential (Yotova et al., 2011) , and cell motility may be important in the endometrial spreading and invasion (Gentilini et al., 2010) , we also investigated this aspect. Our results show that SST and its analogues counteracted PDGF-induced ESC and T HESC motility. Accordingly, SST was previously found to inhibit PDGF-induced migration of neuroblastoma SY5Y cells (Pola et al., 2003) . In a previous study, both high and low concentrations of octreotide were shown to inhibit ESC basal migration (Fasciani et al., 2010) . Here, octreotide did not inhibit ESC motility in the absence of PDGF. This difference is likely due to the lower time considered in our experiment (16 versus 48 h) and to the different endometrial cell origin (eutopic versus ectopic). The observation that SST and its analogues at high/low concentration had a distinct effect on cell proliferation and migration suggests that ssts may be differently involved in these cell behaviours. Based on the foregoing, the most promising strategy to achieve maximal inhibitory effect on both endometriotic cell proliferation and motility would be to target all ssts.
With regard to CST, this peptide was found here to inhibit ESCs and T HESCs motility, similarly to SST. Moreover, CST counteracted PDGF-induced cell proliferation in T HESCs, whereas it had no effect on primary ESCs, likely reflecting cell type specific GPCR signalling/ trafficking (Koenig and Edwardson, 1996) . While a large number of studies have described CST function in the brain and in the immune system (de Lecea, 2008; van Hagen et al., 2008) , little and conflicting information exists on CST effects on cell growth (Cassoni et al., 2002; Cassoni et al., 2006; Armani et al., 2007; Padova et al., 2008) , and no data are available on cell migration. Nevertheless, a potential inhibitory effect on tumor growth has been proposed (Volante et al., 2008) . In Figure 6 Effects of SST and SOM-230 on ERK1/2 (A and B) and Akt (C and D) phosphorylation. Western blot analysis was performed on lysates from T HESCs stimulated for the indicated times with SST and SOM230 (1000 nM), in either the presence (A and C) or absence (B and D) of PDGF (10 ng/ml). Blots are representative of three independent experiments. Equal protein loading was determined by reprobing with antibodies to the respective total proteins. Graphs represent the densitometric analysis of phosphorylated proteins normalized to total proteins and reported as percent of basal (*P , 0.05 versus time 0; **P , 0.01 versus time 0; # P , 0.05 versus PDGF equal time; ## P , 0.01 versus PDGF equal time; ns, not significant).
The somatostatin system in endometriosis this context, our present work provides new data on CST ability to regulate cell growth and motility, likely acting through ssts. After determining SST effects on ESCs and T HESCs motility and proliferation, we focused on VEGF and MMP-2 gene expression, as they are involved in the pathogenesis and progression of endometriosis (McLaren, 2000; Pitsos and Kanakas, 2009) . SST was found to inhibit VEGF and MMP-2 expression in both cell types. This is in keeping with previous studies (Cascinu et al., 2001; Mentlein et al., 2001; Kumar et al., 2004) ; however this is the first evidence in the context of endometriosis, even if its functional implications in vivo should be further evaluated.
We finally assessed the signaling pathway elicited by PDGF and SST. PDGF was previously found to activate ERK1/2 and Akt in human endometrial cells, and both these pathways are required for , assessed by the Alamar blue and b-actin reorganization, respectively. PDGF was used at 25 ng/ml in proliferation experiments and at 10 ng/ml in motility experiments. Results are expressed as percent of control (PDGF-treated cells) and are the mean + SEM of four independent experiments (*P , 0.05, **P , 0.01 versus control; ns, not significant).
PDGF-induced ESCs migration (Gentilini et al., 2007) . Furthermore, sustained ERK1/2 activation may play a major role in endometriotic cell proliferation and motility (Yoshino et al., 2004; Murk et al., 2008) . Our present findings confirm that PDGF stimulates Akt and ERK1/2 in endometrial cells, and most of all suggest that SST and SOM230 inhibit both basal and PDGF-induced ERK1/2 activation. Conversely, they did not reduce PDGF-induced Akt phosphorylation. Altogether, these findings suggest that SST mainly acts via ERK1/2 signaling to counteract PDGF actions in endometriosis. This concept is supported by other reports showing that SST and its analogues decrease growth factors-stimulated MAPK activity (Cattaneo et al., 1996; Held-Feindt et al., 2001; Pola et al., 2003) generally through activation of specific phosphotyrosine phosphatases (PTPs; Pulido et al., 1998; Barbieri et al., 2008; Florio, 2008) . Curiously, besides the ERK1/ 2 dephosphorylation at 30 min, we observed a transient ERK1/2 and Akt phosphorylation, that was only appreciable at 5 min. Several studies reported the ability of SST or its analogues to induce early transient phosphorylation of Akt (Oomen et al., 2002; Ghosh et al., 2006) , ERK1/2 (Florio et al., 1999; Grant et al., 2008; Vockel et al., 2011) or both (Sellers et al., 2000; Hagemeister et al., 2010) . These effects have been attributed to the rapid activation of PI3K by G proteins (Florio et al., 1999; Smalley et al., 1999; Sellers et al., 2000; Hagemeister et al., 2010) likely via their Gbg subunits (Florio et al., 1999; Sellers et al., 2000) . Notably, PI3K plays a pivotal role in stimulating cell migration (Lauffenburger and Horwitz, 1996) and its transient activation could explain our finding that SST, octreotide and the sst1 agonist slightly increased basal T HESC motility. Consistently, a PI3K-dependent SST migratory activity was observed with transient Erk1/2 and Akt/PKB phosphorylation in haematopoietic progenitor cells (Oomen et al., 2002) . However, in our cells SST effect on basal cell motility was very small compared with that induced by PDGF, supporting the concept that the final outcome on cell behaviour mostly depends on the duration and intensity of signaling pathways activation (Marshall, 1995) .
In conclusion, this work shows that SST, CST and their receptors are expressed in endometriotic tissues and cells, and that SST and its analogues exert distinct inhibitory effects on PDGF-induced endometrial cell proliferation and motility. Moreover, we show a marked VEGF and MMP-2 mRNA down-regulation and ERK1/2 inhibition by SST. These findings provide a cellular and mechanistic basis to understand the potential role of SST, CST and their receptors in the pathophysiology of endometriosis and suggest potential clinical perspectives for the treatment of this disease.
